The FDA provided guidance on the design of the APOLLO post-marketing confirmatory trial, which will support an accelerated approval filing for bitopertin. Disc plans to submit a New Drug ...
The recent FDA Type C meeting resulted in an alignment on dual primary endpoints for the APOLLO trial, which include reduction in PPIX and the average final month time spent in sunlight without pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback